AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02107885
Drug: DS-1971
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects in each group will receive DS-1971.
Trial: NCT02107885
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 subjects in each group will receive placebo.
Trial: NCT00674921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch, magnesium stearate, sodium lauryl sulphate
Trial: NCT00913822
Drug: Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
RxNorm normalized name: desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02182518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during run-in period
Trial: NCT01599884
Drug: Oral acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Identical placebo pills twice daily for 8 weeks
Trial: NCT03705234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Trial: NCT01599286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
Trial: NCT02701673
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Trial: NCT02701673
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
Trial: NCT00003287
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003287
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003287
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03399448
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Trial: NCT00772759
Drug: AZD3199 Turbuhaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
Trial: NCT00772759
Drug: Placebo Turbuhaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple (o.d. for 12 days)
Trial: NCT01276704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains same filler materials as commercially available Brevail® but without active SDG.
Trial: NCT02235324
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02235324
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06278493
Drug: AL2846 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL2846 is a multi -target receptor tyrosine kinase inhibitor.
Trial: NCT00481936
Drug: VB6-845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion once weekly for 4 weeks
Trial: NCT02769793
Drug: Levodopa dispersible
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Trial: NCT02769793
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
Trial: NCT04246060
Drug: Cysteamine Bitartrate
RxNorm normalized name: Cysteamine Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT
Trial: NCT00319917
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01829516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo
Trial: NCT02862574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once weekly
Trial: NCT02862574
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally weekly as part of the participant's current treatment regimen
Trial: NCT02862574
Drug: TNF Inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Trial: NCT02749747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg placebo once a day use for 60 days
Trial: NCT04870866
Drug: Nicotinamide ribonucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two year intervention
Trial: NCT03733327
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT02012517
Drug: Prolonged antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01421056
Drug: CHF 5074 2x
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
Trial: NCT01822925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
Trial: NCT01517984
Drug: Standard Immunosuppressive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Trial: NCT02243358
Drug: Folfox6
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03070678
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT05456048
Drug: VAH regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Trial: NCT05456048
Drug: VEN+HMA regimen
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-28; AZA was used at the dose of 75 mg/m2, day 1-7 or DEC 20mg/m2 day 1-5. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Trial: NCT03808935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
Trial: NCT01323608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00132730
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00320606
Drug: Immunosuppression Withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
Trial: NCT00123565
Drug: Hexadecasaccharide (SR123781A)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01999192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical end formulation buffer
Trial: NCT00718315
Drug: erythromycin [Eritex]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical, daily for 30 days.
Trial: NCT00718315
Drug: Fisiogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical, daily for 30 days
Trial: NCT02906111
Drug: estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse
Trial: NCT03825705
Drug: TQB2450 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT03132142
Drug: Vehicle patch
RxNorm normalized name: EXYDERM Transdermal Vehicle Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Trial: NCT00399529
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
Trial: NCT00223951
Drug: R89674 (generic name not yet established)
RxNorm normalized name: forget-me-not extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518479
Drug: Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172014
Drug: midazolam and fentanyl citrate infusion
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
Trial: NCT04435158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection
Trial: NCT01798602
Drug: Rosuvastatin or identical placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet crushed for administration via feeding tube
Trial: NCT01798602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo for rosuvastatin
Trial: NCT00454116
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02466828
Drug: Feraheme®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
Trial: NCT00093509
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
Trial: NCT02468583
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT02468583
Drug: TCA IR 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT00863161
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, oral, single dose
Trial: NCT03763630
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered in same frequency and manner as intervention
Trial: NCT01493414
Drug: INC424
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
Trial: NCT03739528
Drug: Tobramycin + Dexamethasone
RxNorm normalized name: dexamethasone / tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
Trial: NCT00579644
Drug: Combination of Minocycline and MTX or MTX alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg
Trial: NCT00579644
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study.
Trial: NCT02249078
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 solution for injection
Trial: NCT02249078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2-mL vial solution for injection
Trial: NCT02957630
Drug: 15 mg E4/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Trial: NCT02957630
Drug: 30 mcg EE/150 mcg LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mcg EE combined with 150 mcg LNG administered in a 21/7-day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Trial: NCT02957630
Drug: 20 mcg EE/3 mg DRSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
Trial: NCT01108601
Drug: Ringer's Lactate (0.03% Ciprofloxacin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
Trial: NCT03528902
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02935322
Drug: 0.2 % NaF mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period.
Trial: NCT04162834
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Trial: NCT02690142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose i.v.
Trial: NCT02690142
Drug: ABY-035 i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose i.v.
Trial: NCT02690142
Drug: ABY-035 s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose s.c.
Trial: NCT04309643
Drug: Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive in the form of 1 fixed combination tablet of Seasonique or generic equivalent (0.03 mg EE / 0.15 mg LNG)
Trial: NCT01731925
Drug: Placebo (for sunitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00940602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
Trial: NCT01854528
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT00001561
Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH
RxNorm normalized name: vaccinia immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01474109
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo once daily
Trial: NCT00862940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets twice daily
Trial: NCT04445948
Drug: Clarithromycin 500 milligrams Tablets
RxNorm normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Macrolide antibiotic
Trial: NCT03732469
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
Trial: NCT03732469
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
Trial: NCT02434861
Drug: Cooperstown Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
Trial: NCT02181920
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02181920
Drug: Diclofenac placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003525
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT02476448
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used to distend the bladder for cystoscopic evaluation
Trial: NCT02476448
Drug: Dextrose 10%
RxNorm normalized name: DEXTROSE 10% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used to distend the bladder for cystoscopic evaluation
Trial: NCT03688971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT00451230
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05231863
Drug: TKIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tyrosine kinase inhibitors based therapy
Trial: NCT00887354
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly: Administered orally~Daily: Administered subcutaneously
Trial: NCT02784340
Drug: Bupivicaine and Fentany
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005979
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005979
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005979
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01092221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 capsule, 300 mg, BID
Trial: NCT01597739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=capsule; route=oral use; twice daily.